COVID Vaccine Distribution Plan From National Academies Leaves Room For Adjustments Based On Trial Results
Draft allocation framework expects health care workers would take up much of the initial vaccine supply and suggests the elderly and people with two comorbid conditions receive vaccination next. NAM suggests states get a population-based allotment, leaving local officials to make many of the tough decisions under the framework, which could be adjusted based on clinical trial data.
You may also be interested in...
Advisory Committee on Immunization Practices work group also says previous infection with SARS-CoV-2 should not exclude someone from receiving vaccine if they are in one of the early groups recommended for prioritization; ACIP group unveils updated ethical principles intended to guide vaccine allocation decisions.
FDA indicates it expects sponsors and other government agencies to come up with ways to fulfill its request for placebo-controlled studies post-emergency use authorization of COVID-19 vaccines, but neither it nor vaccines advisory committee see a clear way to do this.
US FDA has the unenviable task of picking the most important adverse events to track once coronavirus vaccinations begin; CDC's list will need to be winnowed to 10-20 to make the surveillance feasible, and which AEs make the cut may be informed by the vaccine trials, as well as clinical experience with COVID infections.